Plerixafor: potential role in acute leukemia therapy

Bibliography

• MKucia, RReca, KMierkus, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23:879-94
   PubMed Web of Science ®Google Scholar
• SFreuhauf. Current clinical indications for plerixafor. Transfus Med Hemother 2013;40:248-50
   Google Scholar
• GMKeating. Plerixafor a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011;71:1623-47
   PubMed Web of Science ®Google Scholar
• GCalandra, GBridger, SFricker. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010;341:173-91
   PubMed Web of Science ®Google Scholar
• EJantunen, VVarmavuo. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. Expert Opin Biol Ther 2014;14:851-61
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures, 2014. American Cancer Society, Atlanta; 2014
   Google Scholar
• JPPatel, MGonen, MEFigueroa, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-89
   PubMed Web of Science ®Google Scholar
• LCJVan den Berk, Avan der Veer, MEWillemse, et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. Br J Haematol 2014;166:240-9
   PubMed Web of Science ®Google Scholar
• DKarpova, KDauber, GSpohn, et al. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 2013;27:2322-31
   PubMed Web of Science ®Google Scholar
• SiSee comment in PubMed Commons belowson EAR. BSMagoon, LLi, et al. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in an in vivo model of high-risk (HR) pediatric acute lymphoblastic leukemia (ALL). Blood (American Society of Hematology Annual Meeting) 2014;124:abstract 3707
   Google Scholar
• MRKuhne, TMulvev, BBelanger, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013;19:357-66
   PubMed Web of Science ®Google Scholar
• PSBecker, JMForan, JKAltman, et al. Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936764), an anti-CXCR4 antibody, in relapsed/refractory acute myeloid leukemia. Blood (American Society of Hematology annual meeting) 2014;124:abstract 386
   Google Scholar
• APeled, MAbraham, IAvivi, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 2014;20:469-79
   PubMed Web of Science ®Google Scholar
• RKHopman, JFDiPersio. Advances in stem cell mobilization. Blood Rev 2014;28:31-40
   PubMed Web of Science ®Google Scholar
• ZZeng, IJSamudio, MMunsell, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006;5:3113-21
   PubMed Web of Science ®Google Scholar
• FLanza, AGardellini, DLaszlo, et al. Plerixafor: what we still have to learn. Expert Opin Biol Ther 2015;15:143-7
   PubMed Web of Science ®Google Scholar
• ALevoye, KBalabanina, FBaleux, et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G-protein signaling. Blood 2009;113:6085-93
   PubMed Web of Science ®Google Scholar
• EDeClercq. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 2005;5:805-24
   PubMedGoogle Scholar
• GEDeGreef, EBraakman, WGAlemayehu, et al. Lymphocyte and hematopoietic stem and progenitor cell (HSPC) subsets mobilized by either plerixafor or G-CSF : a retrospective comparison of grafts harvested in healthy allogeneic stem cell donors. Blood (American Society of Hematology Meeting) 2014;124:abstract 2451
   Google Scholar
• SPFricker. Physiology and pharmacology of plerixafor. Transfus Med Hemother 2013;40:237-45
   PubMed Web of Science ®Google Scholar
• EMA package insert. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001030/human_med_000910.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Plerixafor package insert. Genyme Corp. Copyright 2014. Available from: www.mozobil.com/media/pdf/Mozobil_PM.pdf
   Google Scholar
• NALack, BGreen, DCDale, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005;77:427-36
   PubMed Web of Science ®Google Scholar
• MKonopleva, MAndreeff. Targeting the leukemia microenvironment. Curr Drug Targets 2007;8:685-701
   PubMed Web of Science ®Google Scholar
• QMa, DJones, BRBorghesani, et al. Impaired-B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4 and SDF-1 deficient mice. Proc Natl Acad Sci USA 1998;95:9443-53
   Google Scholar
• JKahn, TByk, LJansson-Sjostrand, et al. Overexpression of CXCR4 on human CD3+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004;103:2942-9
   PubMed Web of Science ®Google Scholar
• CVoermans, WPvan Hesse, Ide Jong, et al. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 2002;16:650-7
   PubMed Web of Science ®Google Scholar
• OKollet, IPetit, JKahn, et al. Human CD34+CXCR4- sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 2002;100:2778-86
   PubMedGoogle Scholar
• TLapidot, OKollet. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002;16:1992-2003
   PubMed Web of Science ®Google Scholar
• JABurger, APeled. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52
   PubMed Web of Science ®Google Scholar
• DJCeradini, ARKulkarni, MJCallaghna, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:358-64
   Google Scholar
• TLapidot, IPetit. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973-81
   PubMed Web of Science ®Google Scholar
• MBMeads, LAHazlehurst, WSDalton. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26
   PubMed Web of Science ®Google Scholar
• MKonopleva, SKonoplev, WHu, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002;16:1713-24
   PubMed Web of Science ®Google Scholar
• EJCRombouts, BPaivic, BLowenberg, et al. Relation between CXCR4 expression, FLT3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004;104:550-7
   PubMed Web of Science ®Google Scholar
• PBecker, KJKopecky, ANWilks, et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009;113:866-74
   PubMed Web of Science ®Google Scholar
• EARSison, DMagoon, LLi, et al. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget 2014;5:8947-58
   PubMed Web of Science ®Google Scholar
• STavor, IPetit, SProozov, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD-SCID mice. Cancer Res 2004;64:12817-24
   Google Scholar
• YZhang, SPatel, HAbdelouahab, et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis 2012;3:e396
   PubMed Web of Science ®Google Scholar
• JLLiesveld, JBechelli, KRosell, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007;31:1553-63
   PubMed Web of Science ®Google Scholar
• STavor, MEisenbach, JJacob-Hirsch, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008;22:2151-8
   PubMed Web of Science ®Google Scholar
• BNervi, PRamirez, MPRettig, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009;113:6206-24
   PubMed Web of Science ®Google Scholar
• GUy, MPRettig, IHMotabi, et al. A phase1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119:3917-24
   PubMed Web of Science ®Google Scholar
• GJRoboz, JMScandura, ERitchie, et al. Combining decitabine with plerixafor in newly diagnosed older patients with AML. Blood (ASH annual meeting) 2013;122:abstract 615
   Google Scholar
• JNAllan, GJRoboz, EJFeldman, et al. Interleukin 2 receptor –α(CD25) expression is associated with shortened overall survival and resistance to induction therapy with plerixafor and decitabine in older patients with newly diagnosed acute myeloid leukemia (AML). Blood (American Society of Hematology Annual Meeting) 2014;124:abstract 1041
   Google Scholar
• GLUy, DAvigan, JECortes, et al. Safety and tolerability of plerixafor in combination with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia-preliminary results for a phase I study. Blood (ASH Annual Meeting Abstracts) 2011;118:abstract 82
   Google Scholar
• TMCooper, SDBacker, JDirenzo, et al. Chemosensitization and mobilization of AML/ALL/MDS with plerixafor (AMD3100), a CXCR4 antagonist: a phase I study of plerixafor + cytarabine and etoposide in pediatric patients with acute leukemia and MDS. Blood (ASH Annual Meeting Abstract) 2013;122(21):abstract 2680
   Google Scholar
• AJacobi, SThieme, RLehmann, et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol 2010;38:180-90
   PubMed Web of Science ®Google Scholar
• MAndreeff, ZZeng, MAKelly, et al. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by Plerixafor/G-CSF/sorafenib: results from a phase I trial in relapsed/refractory AML patients. Blood (ASH annual meeting) 2012;120:abstract 142
   Google Scholar
• ASpiegel, OKollet, APeled, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004;103:2900-7
   PubMed Web of Science ®Google Scholar
• JGJuarez, MThien, ADela Pena, et al. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br J Haematol 2009;145:491-9
   PubMed Web of Science ®Google Scholar
• RMelo, ALAlonghini, LBigarella, et al. CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. PLoS One 2014;9:e85926
   PubMed Web of Science ®Google Scholar
• JABurger, ABurkel. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007;137:288-96
   PubMed Web of Science ®Google Scholar
• SMDevine, RVij, MRettig, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-3
   PubMed Web of Science ®Google Scholar
• ALundqvist, ALSmith, YTakahashi, et al. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol 2013;191:6421-49
   Google Scholar
• BLowenberg, Wvan Putten, MTheobald, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52
   PubMed Web of Science ®Google Scholar
• AMandawat, WFiskus, KMBuckley, et al. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 level s and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 2010;166:5306-15
   Google Scholar